S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
OTCMKTS:BRTX

BioRestorative Therapies Competitors

$0.02
0.00 (0.00 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.02
$0.05
Volume25.72 million shs
Average Volume47.53 million shs
Market Capitalization$26.23 million
P/E RatioN/A
Dividend YieldN/A
Beta89.53

Competitors

BioRestorative Therapies (OTCMKTS:BRTX) Vs. BXRX, GRNV, EMMA, CCEL, CLBS, and CTYX

Should you be buying BRTX stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to BioRestorative Therapies, including Baudax Bio (BXRX), GreenVision Acquisition (GRNV), Emmaus Life Sciences (EMMA), Cryo-Cell International (CCEL), Caladrius Biosciences (CLBS), and Curative Biotechnology (CTYX).

Baudax Bio (NASDAQ:BXRX) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Baudax Bio and BioRestorative Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Baudax Bio00203.00
BioRestorative Therapies0000N/A

Baudax Bio currently has a consensus target price of $13.50, indicating a potential upside of 864.29%. Given Baudax Bio's higher possible upside, equities research analysts plainly believe Baudax Bio is more favorable than BioRestorative Therapies.

Volatility & Risk

Baudax Bio has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 89.53, indicating that its share price is 8,853% more volatile than the S&P 500.

Insider and Institutional Ownership

7.9% of Baudax Bio shares are held by institutional investors. 13.1% of Baudax Bio shares are held by company insiders. Comparatively, 12.2% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Baudax Bio and BioRestorative Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baudax BioN/AN/A$-32,560,000.00($3.48)-0.40
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A

BioRestorative Therapies has higher revenue and earnings than Baudax Bio.

Profitability

This table compares Baudax Bio and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Baudax BioN/AN/AN/A
BioRestorative TherapiesN/AN/AN/A

Summary

Baudax Bio beats BioRestorative Therapies on 4 of the 7 factors compared between the two stocks.

GreenVision Acquisition (NASDAQ:GRNV) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for GreenVision Acquisition and BioRestorative Therapies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GreenVision Acquisition0000N/A
BioRestorative Therapies0000N/A

Earnings and Valuation

This table compares GreenVision Acquisition and BioRestorative Therapies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GreenVision AcquisitionN/AN/AN/AN/AN/A
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A

GreenVision Acquisition has higher earnings, but lower revenue than BioRestorative Therapies.

Institutional & Insider Ownership

67.7% of GreenVision Acquisition shares are held by institutional investors. 12.2% of BioRestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares GreenVision Acquisition and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GreenVision AcquisitionN/AN/AN/A
BioRestorative TherapiesN/AN/AN/A

Summary

BioRestorative Therapies beats GreenVision Acquisition on 2 of the 3 factors compared between the two stocks.

Emmaus Life Sciences (OTCMKTS:EMMA) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Volatility & Risk

Emmaus Life Sciences has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 89.53, suggesting that its share price is 8,853% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Emmaus Life Sciences and BioRestorative Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emmaus Life Sciences0000N/A
BioRestorative Therapies0000N/A

Valuation and Earnings

This table compares Emmaus Life Sciences and BioRestorative Therapies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emmaus Life Sciences$1.32 million52.33$-2,370,000.00N/AN/A
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A

Emmaus Life Sciences has higher revenue and earnings than BioRestorative Therapies.

Insider and Institutional Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Comparatively, 12.2% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Emmaus Life Sciences and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emmaus Life SciencesN/AN/AN/A
BioRestorative TherapiesN/AN/AN/A

Summary

Emmaus Life Sciences beats BioRestorative Therapies on 4 of the 6 factors compared between the two stocks.

BioRestorative Therapies (OTCMKTS:BRTX) and Cryo-Cell International (OTCMKTS:CCEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Earnings & Valuation

This table compares BioRestorative Therapies and Cryo-Cell International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A
Cryo-Cell International$31.80 million2.14$2.29 millionN/AN/A

Cryo-Cell International has higher revenue and earnings than BioRestorative Therapies.

Insider & Institutional Ownership

1.0% of Cryo-Cell International shares are owned by institutional investors. 12.2% of BioRestorative Therapies shares are owned by company insiders. Comparatively, 53.8% of Cryo-Cell International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

BioRestorative Therapies has a beta of 89.53, indicating that its stock price is 8,853% more volatile than the S&P 500. Comparatively, Cryo-Cell International has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

Profitability

This table compares BioRestorative Therapies and Cryo-Cell International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioRestorative TherapiesN/AN/AN/A
Cryo-Cell International10.39%-58.74%7.30%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioRestorative Therapies and Cryo-Cell International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioRestorative Therapies0000N/A
Cryo-Cell International0000N/A

Summary

Cryo-Cell International beats BioRestorative Therapies on 6 of the 9 factors compared between the two stocks.

Caladrius Biosciences (NASDAQ:CLBS) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Risk and Volatility

Caladrius Biosciences has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 89.53, indicating that its share price is 8,853% more volatile than the S&P 500.

Profitability

This table compares Caladrius Biosciences and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Caladrius BiosciencesN/A-68.33%-57.61%
BioRestorative TherapiesN/AN/AN/A

Institutional & Insider Ownership

9.0% of Caladrius Biosciences shares are owned by institutional investors. 10.3% of Caladrius Biosciences shares are owned by company insiders. Comparatively, 12.2% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Caladrius Biosciences and BioRestorative Therapies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Caladrius BiosciencesN/AN/A$-19,360,000.00($1.88)-1.02
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A

BioRestorative Therapies has higher revenue and earnings than Caladrius Biosciences.

Analyst Recommendations

This is a summary of recent ratings and price targets for Caladrius Biosciences and BioRestorative Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Caladrius Biosciences01302.75
BioRestorative Therapies0000N/A

Caladrius Biosciences currently has a consensus price target of $9.00, indicating a potential upside of 371.20%. Given Caladrius Biosciences' higher possible upside, equities research analysts plainly believe Caladrius Biosciences is more favorable than BioRestorative Therapies.

Summary

BioRestorative Therapies beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.

Curative Biotechnology (OTCMKTS:CTYX) and BioRestorative Therapies (OTCMKTS:BRTX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Curative Biotechnology and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Curative BiotechnologyN/AN/AN/A
BioRestorative TherapiesN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Curative Biotechnology and BioRestorative Therapies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Curative Biotechnology0000N/A
BioRestorative Therapies0000N/A

Risk & Volatility

Curative Biotechnology has a beta of -31.94, meaning that its stock price is 3,294% less volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 89.53, meaning that its stock price is 8,853% more volatile than the S&P 500.

Earnings and Valuation

This table compares Curative Biotechnology and BioRestorative Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curative BiotechnologyN/AN/AN/AN/AN/A
BioRestorative Therapies$110,000.00238.43$-12,520,000.00N/AN/A

Curative Biotechnology has higher earnings, but lower revenue than BioRestorative Therapies.

Summary

BioRestorative Therapies beats Curative Biotechnology on 2 of the 2 factors compared between the two stocks.


BioRestorative Therapies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BXRX
Baudax Bio
1.4$1.40flat$98.20 millionN/A-0.40Analyst Upgrade
GRNV
GreenVision Acquisition
0.3$10.16flat$73.03 millionN/A0.00
EMMA
Emmaus Life Sciences
0.2$1.41flat$69.07 million$1.32 million0.00Gap Down
CCEL
Cryo-Cell International
1.0$9.00flat$67.91 million$31.80 million22.50High Trading Volume
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.91flat$62.97 millionN/A-2.98Earnings Announcement
News Coverage
CTYX
Curative Biotechnology
0.0$0.15flat$55.11 millionN/A0.00Gap Down
PFHOD
Pacific Health Care Organization
0.5$1.25flat$52.48 million$6.80 million0.00Gap Up
BRTXQ
BioRestorative Therapies
0.0$0.02flat$26.23 million$110,000.00-0.01Gap Down
PFHO
Pacific Health Care Organization
0.8$1.14flat$14.59 million$7.33 million0.00Gap Down
GNOW
American Caresource
0.7$0.03flat$465,000.00N/A0.00News Coverage
Gap Down
HYBE
Hybrid Energy
0.0$0.00flat$0.00N/A0.00Gap Up
QMED
QMed
0.2$0.00flat$0.00N/A0.00Gap Up
This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.